Also AMERICAN Regent has been given rights for entire operations of of injectafer in USA. I am not sure what arrangements CSL have with them, but I won’t expect much more than royalty type of income out of this from USA.
However the EPS forecast of 12.50+ for 2025 still stands considering plasma volume and margin increases, availability of plasma, Vifor integration benefits, A$ Weakness. This results will be good CAGR rate and carry high PE multiple as CSL usually do.
Also AMERICAN Regent has been given rights for entire operations...
-
- There are more pages in this discussion • 51 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add CSL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$293.58 |
Change
-2.420(0.82%) |
Mkt cap ! $142.3B | |||
| Open | High | Low | Value | Volume |
| $294.28 | $295.68 | $293.35 | $44.28M | 150.6K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 18 | $293.56 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $293.58 | 56 | 4 |
View Market Depth
| Last trade - 12.34pm 18/09/2024 (20 minute delay) ? |
| CSL (ASX) Chart |